Thank you to @Psyched_Alpha for featuring Terran’s recently-granted composition-of-matter patent on #methylone in their recent review of the landscape. https://t.co/E9ZGJVngXK Terran’s patent covers the salts and polymorphs of racemic methylone HCl (US12,234,216B2), and these

We’re proud to announce that we’ve been granted a U.S. patent for the world’s first new polymorphs of #methylone hydrochloride (US-12234216-B2). Methylone is a rapid acting empathogen with a differentiated profile from MDMA and Terran is currently developing methylone as a

Terran CEO Sam Clark @neonneurons was recently featured on The BioHub podcast to discuss recent advances in #schizophrenia, including TerXT, our combination of novel prodrugs of xanomeline and trospium (the same active ingredients in FDA-approved Cobenfy) https://t.co/R2DrS4x6Vz

We are honored to receive BioTech Breakthrough’s Analytics Innovation of the Year award for NM-101, our FDA-cleared software platform to analyze neuromelanin MRI scans. https://t.co/9amzY3NV09 With this new technology we aim to aid in the evaluation of complex neuropsychiatric

The Terran team is thrilled to have been selected as a Fierce Life Science Innovation Award finalist for our FDA-approved NM-101 software technology to aid in the evaluation of #ParkinsonsDisease and other neuropsychiatric conditions. We are honored to be recognized alongside the

Terran's CEO Sam Clark @neonneurons moderated an @HCPLiveNews panel alongside key opinion leaders Dr. Andrew Cutler and Dr. Rishi Kakar (lead investigator on the KarXT trials), to discuss the FDA approval of KarXT (Cobenfy) for #schizophrenia, and what this means for patients and

As a global leader in psychedelic manufacturing and supply, Terran is excited to provide psilocybin, LSD, and DMT, to Gitte Moos Knudsen’s lab at @CopenhagenNeuro to support their groundbreaking research in psychiatry and neurology. These are some of the many psychedelic

Terran’s CEO Sam Clark @neonneurons connected with @kellyb720 at @pharmavoice for her article alongside @KarunaTx founder Andrew Miller to discuss the recent FDA approval of KarXT (Cobenfy) for #schizophrenia and future innovations like TerXT. https://t.co/35P63OvJrE

Terran CEO Sam Clark @neonneurons shared his thoughts on what the FDA’s recent approval of KarXT (Cobenfy) means for #schizophrenia patients and for new innovation in this article by @MelissaRudy at @FoxNews alongside commentary by @bmsnews CEO: https://t.co/PRVyaUDuLU

Today at 10:00am ET, Terran’s founder and CEO, Sam Clark, MD PhD @neonneurons will be presenting on our unique prodrug approach to create novel therapeutics like TerXT for the treatment of #schizophrenia. Register for the webinar below:

Late last night the FDA announced they had approved the new #schizophrenia drug Cobenfy (formerly KarXT). Terran CEO Sam Clark @neonneurons spoke with @ChelsieDerman at @HCPLiveNews, and shared his thoughts on this big win for patients and the implications for new innovation.